ParcelBio
Elevated mRNA for transformative medicines.
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
ParcelBio is engineering a new class of mRNA medicines designed to deliver unprecedented potency and durability. Its proprietary APEXm™ platform uses novel RNA domains to enhance protein expression and extend activity, enabling therapies that reach the thresholds required for meaningful, and potentially curative, clinical outcomes. The company is advancing programs in autoimmune disease, oncology, and encoded protein therapeutics. ParcelBio is a Y Combinator company (Winter 2024). YC-listed status: Active.
- Website
- parcelbio.com
- Location
- San Francisco, CA, USA
- Added via
- web
- Ownership
- unclaimed
Where to go
Products
- APEXm — Proprietary mRNA platform that achieves dramatically higher and more durable protein expression for next-generation therapeutics. · Other
Links
- Y Combinator profileycombinator